Phosphodiesterase 4 (PDE4) (PDE4)

Phosphodiesterase 4 (PDE4) is a family of enzymes that specifically catalyze the hydrolysis of cyclic adenosine monophosphate (cAMP), a key second messenger in various signaling pathways [1, 3]. The PDE4 family consists of four isoforms—PDE4A, PDE4B, PDE4C, and PDE4D—which are encoded by distinct genes and exhibit tissue-specific expression patterns, particularly in immune cells and the central nervous system [1, 2]. By controlling cAMP levels, PDE4 serves as a master regulator of inflammatory and immune responses, making it a significant therapeutic target [6, 12]. PDE4 inhibitors, such as roflumilast and apremilast, are clinically used to treat chronic inflammatory diseases like COPD, psoriasis, and psoriatic arthritis [5, 7]. However, the therapeutic index of non-selective inhibitors is often constrained by dose-limiting side effects, most notably nausea and emesis, which are thought to be mediated by PDE4D inhibition in the brain's area postrema [1, 11]. Ongoing drug development efforts aim to create isoform-selective or tissue-targeted inhibitors to minimize these adverse effects while maintaining anti-inflammatory efficacy [6, 8].

Other names

cAMP-specific 3',5'-cyclic phosphodiesterase 4PDE4 familyPhosphodiesterase IVPDE4APDE4BPDE4CPDE4D

Inhibition of PDE4 enzymes prevents the hydrolysis of cyclic adenosine monophosphate (cAMP), leading to increased intracellular cAMP levels. This elevation activates protein kinase A (PKA) and Epac (exchange protein activated by cAMP), which in turn suppress the production of pro-inflammatory cytokines (such as TNF-alpha, IL-17, and IL-23) and modulate the activity of various immune cells, including neutrophils, macrophages, and T cells.